Recent developments highlight Silexion's clinical advancement of SIL204, capital raising activities, and participation in industry events.

• Silexion reported positive preclinical data for SIL204 in lung cancer and pancreatic cancer models, advancing towards Phase 2/3 clinical trials [N3][N4].
• The German BfArM cleared Silexion's Phase 2/3 trial for SIL204 in pancreatic cancer [N1].
• The company entered a strategic collaboration with Catalent to advance SIL204 development and manufacturing [N6].
• Silexion completed toxicology studies and initial orthotopic pancreatic cancer model studies for SIL204 [N4].
• The company raised $2.5 million through an offering to advance the SIL204 clinical trial [N1].
• Silexion raised $1 million through warrant exercises to support corporate operations [N5].
• The company announced a 1-for-10 reverse share split [N1].
• Silexion attended the 7th Annual RNAi-Based Therapeutics Summit to present its technology [N2].

Silexion has advanced SIL204 into Phase 2/3 clinical trials with regulatory clearance, supported by positive preclinical data and strategic collaboration with Catalent. The company has demonstrated ability to raise capital to fund operations and maintains effective internal controls. Continued clinical progress and successful trial outcomes could validate its RNAi therapeutic approach in KRAS-driven cancers, addressing significant unmet medical needs.

Silexion operates in a high-risk clinical-stage biotechnology sector with ongoing net losses and liquidity ratios below 1.0, indicating potential funding challenges. The company faces typical clinical development risks including trial outcomes, regulatory hurdles, and competition. The advanced stage of trials does not guarantee successful commercialization. Dependence on capital raises and collaborations introduces execution risks.

Silexion's moat is based on its proprietary RNAi therapeutic SIL204 targeting KRAS-driven cancers, a challenging and high-need oncology segment. The company has demonstrated preclinical efficacy and progressed to advanced clinical trial stages, supported by strategic partnerships for development and manufacturing. The specialized nature of RNAi technology and focus on KRAS mutations provide potential differentiation, though the company remains in early clinical development with associated risks.

• Clinical Development Risk: Silexion's lead product SIL204 is in Phase 2/3 trials, and clinical outcomes remain uncertain. Failure to demonstrate safety and efficacy could materially impact the company.
• Financial and Liquidity Risk: As of June 30, 2026, the company had a current ratio of 0.94 and a cash ratio of 0.56, indicating potential liquidity constraints that may require additional financing.
• Regulatory Risk: Regulatory approvals are required for commercialization. While the company has clearance for trials in Germany, further approvals are necessary and subject to regulatory review.
• Market and Competitive Risk: The oncology therapeutics market is competitive with multiple approaches targeting KRAS mutations. Silexion faces competition from established and emerging therapies.

• Silexion Therapeutics Corp is a Cayman Islands incorporated company with ordinary shares trading on Nasdaq under the ticker SLXN [S1].
• The company has completed multiple reverse share splits, including a 1-for-15 reverse split effective July 29, 2025 [S1].
• As of March 10, 2026, Silexion had 3,330,785 ordinary shares issued and outstanding [S1].
• Silexion is developing SIL204, an RNA interference (RNAi) therapeutic targeting KRAS-driven cancers, including pancreatic and lung cancers [N3][N4][N6].
• The company has reported positive preclinical data for SIL204 in lung cancer and pancreatic cancer models, including orthotopic pancreatic cancer models [N3][N4][N8].
• Silexion has advanced SIL204 into Phase 2/3 clinical trials, with regulatory clearance from the German BfArM for the Phase 2/3 trial in pancreatic cancer [N1].
• The company has entered a strategic collaboration with Catalent to advance development and manufacturing of SIL204 [N6].
• Silexion has conducted toxicology studies for SIL204 and completed initial studies in orthotopic pancreatic cancer models [N4].
• The company has raised capital through warrant exercises and private placements, including a $3.3 million warrant exercise and a $2.5 million offering to support clinical trial advancement [N1][N5].
• As of June 30, 2026, Silexion reported cash and cash equivalents of $2.229 million and current assets of $3.741 million, with current liabilities of $3.976 million, resulting in a current ratio of 0.94 and a cash ratio of 0.56 [S2].
• The company reported a net loss of $3.551 million for the quarter ended June 30, 2026 [S2].
• Silexion's management has evaluated and concluded that its disclosure controls and internal control over financial reporting were effective as of December 31, 2025 [S1].
• The company is classified as an emerging growth company and a smaller reporting company, not an accelerated filer [S1].
• Silexion participates in industry events such as the 7th Annual RNAi-Based Therapeutics Summit to present its technology and development progress [N2].